Unlock instant, AI-driven research and patent intelligence for your innovation.
Combined vaccine for inhibiting and / or preventing type A streptococcal infection
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A type A streptococcus and streptococcus technology, applied in antibacterial drugs, bacterial antigen components, etc., can solve problems such as hindering vaccine development, lack of serotype crossover, and difficulty in developing vaccines
Active Publication Date: 2015-11-18
HAIKOU PHARMA FACTORY
View PDF2 Cites 3 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
The research and development of Streptococcus A vaccine started as early as the 1920s but has not yet come out. Two important reasons have hindered the development of vaccines: First, there are many serotypes of Streptococcus A, and each serotype lacks crossover, making it difficult to develop a vaccine. Vaccine against all serotypes
Streptococcus A is divided into more than 150 serotypes according to the difference of the M protein of its cell wall, and the number is constantly increasing. It is difficult for a vaccine designed for one serotype to work against another serotype, which has become the primary reason for restricting the development of vaccines.
Second, streptococcal infection is closely related to autoimmune diseases, and vaccines have the risk of causing autoimmune diseases, which greatly hinders the process of vaccine development
Although sortase A immunization also induces the production of antibodies, because it is located in the cell wall, antibodies cannot recognize it and thus cannot exert immune protection
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0061] Embodiment 1, the preparation of combined vaccine component sortase A and C5a protease
[0064] 1) Using the genomic DNA of type A Streptococcus M1 as a template, perform PCR amplification with a primer pair composed of F1 and R1 to obtain a 516bp PCR amplification product, which is the sortase A gene SrtA.
[0067] 2), using restriction endonucleases NdeI and XhoI to double digest the PCR amplified product of step 1, and reclaim the digested product.
[0068] 3) The vector pET28a(+) was double digested with restriction endonucleases NdeI and XhoI, and the vector backbone of about 6000 bp was recovered.
[0069] 4) Ligate the digested product of step 2 with the vector backbone of step 3 to obtain the recombinant plasmid pET28a-SrtA.
[0070] After sequencing, t...
Embodiment 2
[0109] Embodiment 2, the functional research of combined vaccine
[0110] 1. The immune protection of the combined vaccine against Streptococcus A
[0111] The immunogens are grouped as follows:
[0112] Sortase A plus CTB group (SrtA): the sortase A prepared in Example 1 and the adjuvant CTB were mixed according to the mass ratio of 10:1, and immunized, and the immunization dose was 10 μg sortase A / time / piece;
[0113] C5a protein plus CTB group (SCPA): the C5a protease prepared in Example 1 and the adjuvant CTB were mixed according to the mass ratio of 20:1, and immunized, and the immunization dose was 20 μg C5a protein / time;
[0114] Combined vaccine plus CTB group (SrtA / SCPA): Combined vaccine immunization prepared in Example 1, immunization dose is 20 μg C5a protein / time;
[0115] Streptococcus A full bacteria group (GAS): Type A Streptococcus M1 type immunity, the immune dose is 5×10 7 cfu / time;
[0116] PBS group: use PBS (10mMNa 2 HPO 4 , 1.8mMKH 2 PO 4 , 140mM...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The present invention discloses a combined vaccine for inhibiting and / or preventing type A streptococcal infection. The present invention provides a composition for inhibiting streptococcus and / or preventing streptococcal infection, and the composition comprise an immunogen. The immunogen is one of the following 1)-4): 1) the immunogen comprises a sortase A and a C5a protease; 2) the immunogen comprises a sortase A solution and a C5a protease solution; 3) the immunogen comprise a fusion protein containing sortase A and a fusion protein containing C5a protease; and 4) the immunogen comprises a junctional complex of sortase A and polysaccharide and a junctional complex of C5a protease and polysaccharide. The specific amino acid sequence of the sortase A is the N-terminal amino acid residues from site No.22 to No.189 of a sequence 2; and the amino acid sequence of the C5a protease is a sequence 4 in the sequence table. The combined vaccine can be applied to prevention and treatment of mucosal system infections caused a variety of Gram-positive bacteria.
Description
technical field [0001] The invention belongs to the field of biomedicine and relates to a combined vaccine for inhibiting and / or preventing type A streptococcus infection. Background technique [0002] Group A streptococci (hereinafter referred to as Streptococcus A) is a normal flora of the human upper respiratory tract and one of the common clinical Gram-positive opportunistic pathogens, which can cause a variety of diseases, including tonsillitis in mild cases , pharyngitis and various types of skin and soft tissue infections; severe cases are seriously life-threatening, such as pneumonia, bacteremia, toxic shock syndrome and acute necrotizing fasciitis. Streptococcus A is ubiquitous in the tonsils of humans. Once it enters the wound, it has a strong reproductive ability in the human body, can quickly produce toxins, erode muscles and body tissues, and cause patients to become disabled, shock, or even die. "Man-eating fungus". Recurrent streptococcal tonsillitis can lea...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More 
Login to View More 
